Olink Bioscience launches a new product, Proseek™, today. Proseek is a user friendly open assay development reagent kit for the detection and quantification of proteins in serum or plasma samples. It offers the same level of performance as ELISA, but uses extremely low sample volumes; only1 µl is required for each reaction thus enabling the scientist to study precious bio-banked materials and plasma from small laboratory animals. The kit allows researchers to combine their antibodies with Proseek to conveniently set up their own specific assays.

“We are very excited about this new product and the significant contributions it will make to the biomarker research field of guiding drug development and diagnostics research. Proseek delivers excellent assay performance from a simple working procedure. It is a specific, sensitive, and reliable method. It also offers the benefits of detection using real-time PCR, allowing quantification of both relative and absolute protein levels. In early testing this product has been well received by the scientific community both in industry and academia” says Dr Simon Fredriksson, Chief Scientific Officer at Olink Bioscience.

“The low sample consumption and overall immunoassay performance of Proseek has enabled us to access precious and limited biobanked plasma samples, a commonly recurring problem with standard technologies which use 50-100 fold more material. We are now able to perform novel biomarker research studies with the goal of improving early detection of breast and colorectal cancer” says Proseek user Dr. Jan Stenvang, Head of Research, University of Copenhagen.

The Proseek reagents are based on PEA, which is a proximity extension assay technology. A pair of oligonucleotide labeled antibodies, Proseek probes, are allowed to pair-wise bind to the target protein present in the sample in a homogeneous assay, without washing steps. When the two Proseek probes are in close proximity, a new PCR target sequence is formed by a proximity dependent DNA polymerization event. The resulting new sequence is subsequently detected and quantified using standard real-time PCR.

About Olink Bioscience

Olink Bioscience develops cutting-edge technologies for biomolecular analysis for use in research and diagnostics. These novel tools for protein detection and nucleic acid analyses enable researchers to see further into biology revealing new insights into basic science, drug development, and diagnostics.  The products, which are based on a strong intellectual property portfolio, are sold by Olink Bioscience and a global network of distributors.  The company’s proprietary Duolink® product line enables researchers in academia and the pharmaceutical industry to visualize and accurately quantify individual proteins, their interactions and modifications, in unmodified cells and tissues. Such information is crucial to help elucidate disease mechanisms, leading to the development of novel diagnostics, therapeutics, and new drug targets. Olink’s molecular technologies are also commercialized through out-licensing to industry leading partners such as Affymetrix, Life Technologies, and through the spin-out companies Halo Genomics and Qlinea. Olink Bioscience was founded in 2004 and is headquartered in Uppsala, Sweden.

For information please contact:

Björn Ekström                                                                
CEO and President              
Olink Bioscience                                                            
Phone: +46 (0)18 444 39 70                        
email: info@olink.com

Proseek™ and Duolink® are intended for research use only. Proseek™ and Duolink® are not for use in human diagnostic or therapeutic procedures. The following trademarks are owned by Olink AB: Olink®, Olink Bioscience, Duolink®, Proseek™ and PLA®.